Details of the Drug Formulations
General Information of Drug (ID: DM1ECNJ)
| Drug Name | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | Tenofovir alafenamide; Vemlidy | |||||||||||||||||||||||
| Indication |
|
|||||||||||||||||||||||
| Cross-matching ID | ||||||||||||||||||||||||
Full List of Drug Formulations Containing This Drug
References
| 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020 | ||||
|---|---|---|---|---|---|
| 2 | ClinicalTrials.gov (NCT01565850) Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults. U.S. National Institutes of Health. | ||||
